title: One-week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicentre, randomized, double-blind study.
abstract: BACKGROUND
  The metronidazole resistance of Helicobacter pylori strains has increased rapidly.
  
  
  OBJECTIVE
  To evaluate the efficacy and safety of new 1-week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline.
  
  
  METHODS
  One hundred and twenty patients with H. pylori-positive inactive duodenal ulcer or non-ulcer dyspepsia diagnosed by endoscopy were recruited randomly to receive one of two regimens for 7 days: ranitidine bismuth citrate, 350 mg b.d., furazolidone, 100 mg b.d., and either amoxicillin, 1000 mg b.d. (n=60), or tetracycline, 500 mg b.d. (n=60). H. pylori infection was identified by rapid urease testing and histology. 13C-Urea breath test was performed to evaluate the cure of H. pylori infection at least 4 weeks after completion of triple therapy.
  
  
  RESULTS
  The eradication rates of H. pylori by ranitidine bismuth citrate-furazolidone-amoxicillin and ranitidine bismuth citrate-furazolidone-tetracycline regimens were 82% and 85% (P > 0.05), respectively, by intention-to-treat analysis, and 85% and 91% (P > 0.05), respectively, by per protocol analysis. Adverse effects were mild in both ranitidine bismuth citrate-furazolidone-amoxicillin and ranitidine bismuth citrate-furazolidone-tetracycline groups.
  
  
  CONCLUSIONS
  One-week regimens containing ranitidine bismuth citrate, furazolidone and amoxicillin or tetracycline are well tolerated and effective for the eradication of H. pylori.
authors.affiliation: Shanghai Institute of Digestive Disease, Shanghai Second Medical University, Shanghai, China.
authors.forename: H
authors.initials: H
authors.lastname: Lu
authors.forename: D Z
authors.initials: DZ
authors.lastname: Zhang
authors.forename: P J
authors.initials: PJ
authors.lastname: Hu
authors.forename: Z S
authors.initials: ZS
authors.lastname: Li
authors.forename: X H
authors.initials: XH
authors.lastname: Lu
authors.forename: X C
authors.initials: XC
authors.lastname: Fang
authors.forename: S D
authors.initials: SD
authors.lastname: Xiao
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001729:Bismuth / Q000009:adverse effects / Q000627:therapeutic use*; D003967:Diarrhea / Q000139:chemically induced; D004244:Dizziness / Q000139:chemically induced; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D005664:Furazolidone / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000517:prevention & control; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010406:Penicillins / Q000627:therapeutic use; D011446:Prospective Studies; D011537:Pruritus / Q000139:chemically induced; D011899:Ranitidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D013752:Tetracycline / Q000627:therapeutic use; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced
chemical_list: D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D000897:Anti-Ulcer Agents; D010406:Penicillins; D005664:Furazolidone; C073340:ranitidine bismuth citrate; D000658:Amoxicillin; D011899:Ranitidine; D013752:Tetracycline; D001729:Bismuth